The U.S. Department of Commerce’s United States Patent and Trademark Office (USPTO) has issued medical device company Saranas with a patent for bleed monitoring technology. Saranas, which is focused on improving patient outcomes through early detection and monitoring of internal bleeding complications, received Patent No. 11,224,414 from the USPTO.
“As we continue to grow our commercial presence with the Early Bird, we are pleased to secure this important patent that is designed to further expand the implementation of our differentiated bleed monitoring technology,” says Saranas CEO James Reinstein. “This patent award demonstrates Saranas’ commitment to innovation and further strengthens our intellectual property portfolio.”
Titled “Access Closure with Bleed Monitoring,” this key patent allows for embedding a vascular access closure device with the company’s proprietary bleed monitoring technology. Saranas’ Early Bird Bleed Monitoring System is an FDA-approved device for real-time detection and monitoring of endovascular bleed complications.
“From vessel injury to failure of obtaining hemostasis with access closure devices, bleeding complications in interventional procedures continue to pose challenges for clinicians,” says Timothy Henry, MD, MSCAI, Lindner Family Distinguished Chair in Clinical Research and Medical Director of The Carl and Edyth Lindner Center for Research at The Christ Hospital. “Technologies to better manage access site complications are paramount as the continued emergence of percutaneous interventions often require large-bore vascular access.”
For more information, visit www.saranas.com.
